Quick Answer
Selenium Thyroid Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Across studies, PBM was associated with reductions in thyroid autoantibodies, improvements in thyroid hormone indices, and decreases in LT4 dose requirements.
Key Takeaways
- 01Across studies, PBM was associated with reductions in thyroid autoantibodies, improvements in thyroid hormone indices, and decreases in LT4 dose requirements. [Berisha-Muharremi V (2026)]
- 02However, current evidence is limited by the small number of human studies, heterogeneous PBM protocols, and the frequent use of concomitant interventions such as selenium or vitamin D. [Berisha-Muharremi V (2026)]
- 03Chronic autoimmune thyroiditis (CAT), a common autoimmune thyroid disorder, is the leading cause of hypothyroidism in iodine-sufficient regions and is characterized by thyroid autoimmunity, chronic inflammation, and progressive structural thyroid changes. [Berisha-Muharremi V (2026)]
- 04Although levothyroxine (LT4) restores biochemical euthyroidism, it does not directly address the underlying autoimmune process, highlighting the need for adjunctive therapeutic strategies. [Berisha-Muharremi V (2026)]
The current Migaku evidence database contains 2 reusable source documents for Selenium Thyroid Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Across studies, PBM was associated with reductions in thyroid autoantibodies, improvements in thyroid hormone indices, and decreases in LT4 dose requirements. [Berisha-Muharremi V (2026); evidence level 1]
- However, current evidence is limited by the small number of human studies, heterogeneous PBM protocols, and the frequent use of concomitant interventions such as selenium or vitamin D. [Berisha-Muharremi V (2026); evidence level 1]
- Chronic autoimmune thyroiditis (CAT), a common autoimmune thyroid disorder, is the leading cause of hypothyroidism in iodine-sufficient regions and is characterized by thyroid autoimmunity, chronic inflammation, and progressive structural thyroid changes. [Berisha-Muharremi V (2026); evidence level 1]
- Although levothyroxine (LT4) restores biochemical euthyroidism, it does not directly address the underlying autoimmune process, highlighting the need for adjunctive therapeutic strategies. [Berisha-Muharremi V (2026); evidence level 1]
- Graphical abstract A simplified figure displaying the main events leading to Hashimoto's thyroiditis and Grave's disease via Th1 and Th2 activation, and the potential sites of selenium (Se) action. [Duntas LH (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources